RT Journal Article
SR Electronic
T1 Analysis of SARS-CoV-2 Ig seroprevalence in Northern Ireland
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.19.23295776
DO 10.1101/2023.09.19.23295776
A1 Greene, Michelle K
A1 Smyth, Peter
A1 English, Andrew
A1 McLaughlin, Joseph
A1 Bucholc, Magda
A1 Bailie, Janice
A1 McCarroll, Julie
A1 McDonnell, Margaret
A1 Watt, Alison
A1 Barnes, George
A1 Lynch, Mark
A1 Duffin, Kevan
A1 Duffy, Gerard
A1 Lewis, Claire
A1 James, Jacqueline A
A1 Ford, Tom
A1 O’Kane, Maurice
A1 Rai, Taranjit Singh
A1 Bjourson, Anthony J
A1 Cardwell, Christopher
A1 Elborn, J Stuart
A1 Gibson, David S
A1 Scott, Christopher J
YR 2023
UL http://medrxiv.org/content/early/2023/09/20/2023.09.19.23295776.abstract
AB Background With the impact of SARS-CoV-2 upon public health directly and socioeconomically, further information was required to inform policy decisions designed to limit virus spread. This study sought to contribute to serosurveillance work within Northern Ireland to track SARS-CoV-2 progression and guide health strategy.Methods Sera/plasma samples from clinical biochemistry laboratories were analysed for anti-SARS-CoV-2 immunoglobulins (Ig). Samples were assessed using an Elecsys anti-SARS-CoV-2 or anti-SARS-CoV-2 S ECLIA (Roche) on an automated Cobas-e-analyser. Samples were also assessed via ELISA (Euroimmun). A subset of samples assessed via Roche Elecsys anti-SARS-CoV-2 IgG assay were subsequently analysed in an ACE2 pseudoneutralisation assay using a V-PLEX SARS-CoV-2 Panel 7 for IgG and ACE2 by MesoScale Diagnostics Inc.Results Across three testing rounds (June-July 2020, November-December 2020 and June-July 2021 (rounds 1-3 respectively)), 4844 residual sera/plasma specimens were assayed for SARS-CoV-2 Ig. Seropositivity rates increased across the study, peaking at 11.6% during round 3. Varying trends in SARS-CoV-2 seropositivity were noted based on demographic factors. For instance, highest rates of seropositivity shifted from older to younger demographics across the study period. In round 3, alpha (B.1.1.7) variant neutralising antibodies were most frequently detected across age groups, with median concentration of anti-spike protein antibodies elevated in 50-69 year olds and anti-S1 RBD antibodies elevated in over 70s, relative to other age groups.Conclusions With seropositivity rates of <15% across the assessment period, it can be concluded that the significant proportion of the Northern Ireland population had not yet naturally contracted the virus by mid-2021.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectorsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was obtained from the Northern Ireland Biobank. The Northern Ireland Biobank has ethical approval from The Office of Research Ethics Committees Northern Ireland (ORECNI REF 21/NI/0019) and can confer ethical approval for projects which have received material from the bankI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes